AstraZeneca Pharmaceuticals LP
NEWS
The approval was based on data from the Phase III GRECO clinical trial and the Phase I AMES trial.
The U.S. Food and Drug Administration (FDA) rejected the company’s inhaled triple-combination therapy, PT010, now known as Breztri Aerosphere.
PARP inhibitors will be taking center stage at the European Society of Medical Oncology Congress as rival drugmakers aim to show off data that supports broader use of the drug in treating various cancers.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
The importance of artificial intelligence and machine learning is ever-increasing in the world of drug development and AstraZeneca is bolstering its participation in the tech revolution by striking a deal with New York-based Schrodinger to use that company’s advanced computing platform to help accelerate drug discovery efforts.
AstraZeneca had a big weekend, with positive results from two separate clinical trial programs causing stock to jump 3.4%.
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.
JOBS
IN THE PRESS